Direct answer. Heart disease does not automatically prevent sexual activity. Symptoms, recovery and medicines determine individual advice. Nitrates such as GTN can interact dangerously with erectile-dysfunction medicines; seek urgent help for chest pain after one and do not self-administer GTN. NHS angina guidance; CUH nitrate warning.
- Discuss sexual health as part of cardiac recovery, including pain, desire and anxiety.
- A calendar or ability to climb stairs cannot provide individual cardiac clearance.
- Nitrate medicines and selected erection medicines can cause dangerous low blood pressure together.
- Repeated erection problems need assessment; they do not diagnose blocked arteries.
- Do not stop cardiac medicines to improve sexual function or permit an erection drug.
- Sexual counselling has a clinical role, while independent comparative efficacy remains unresolved.
Evidence summary
| Question | Source role | Conclusion and confidence |
|---|---|---|
| Does a heart diagnosis mean no sex? | Selected clinical education | No universal prohibition; current symptoms and recovery matter. |
| Can a leaflet or stair test clear an individual? | Scope limitation | No; neither replaces assessment of the actual condition and procedure. |
| Can nitrates be combined with erection medicines? | Concordant medicine warnings | Dangerous blood-pressure interaction; do not improvise around it. |
| Does erectile dysfunction prove coronary disease? | Multiple-cause education | No. Repeated symptoms warrant assessment, not self-diagnosis. |
| Is counselling a proven event-prevention treatment? | Current guidance with trial gaps | Clinical support role; no independently cleared event benefit established here. |
Confidence is high in the need for condition-specific assessment and urgent attention to warning signs; recommendations are attributed clinical context, not independently certified treatment effects. The treatment section attributes clinical guidance; it does not certify the funding of every underlying intervention trial. Independent comparative outcome certainty and a supplement replacement regimen were not established by this focused review. A public institution or independent review cannot make a sponsored original trial financially independent.
Sexual health, intimacy and different sexual concerns
Sexual health includes desire, arousal, comfort, erections, orgasm, relationships and personally satisfying intimacy. It is broader than intercourse or a medicine that produces an erection. This guide concerns adults and consensual activity; a cardiac diagnosis does not create an obligation to resume sex or satisfy a partner.
Erectile dysfunction, also called impotence, means difficulty getting or keeping an erection. Low desire is a different concern. Occasional difficulty and a recurring problem are not equivalent. The dated NHS erection page supports assessment when symptoms keep happening, but its scheduled review is overdue and no current licensing or success-rate claim is adopted. NHS erection guidance.
Changes can affect anyone after a heart event. NHS coronary recovery information describes worries, relationship strain and possible illness or medicine effects. A GP, nurse or cardiac rehabilitation team can discuss concerns. Someone may want support even without a physical symptom, and partners may have separate fears about causing harm. NHS recovery guidance.
Physical effort, symptoms and multiple causes
Sexual activity can involve physical effort and changes in cardiovascular demand. The important clinical questions are whether symptoms occur, whether the condition is controlled, and whether recovery imposes restrictions. NHS angina information says well-controlled symptoms can allow most usual activities, including sex; this is general education, not clearance for every severity or diagnosis. NHS angina guidance.
Several factors may contribute to sexual difficulties. The current NHS low-libido page lists stress, anxiety, depression, relationship difficulties, hormonal changes, medicines and long-term conditions including heart disease. A new problem should not automatically be attributed to one prescription or reduced blood flow. NHS libido guidance.
Erection problems can coexist with hypertension, diabetes, high cholesterol, hormonal problems or distress. This overlap does not make every erection problem an early heart attack warning or validate a home score for coronary narrowing. Assessment needs the history and relevant examination. NHS erection guidance.
Individual recovery advice and sexual-health assessment
Ask the cardiac team what activity is appropriate now and what should prompt review. State the actual diagnosis, recent event or procedure, symptoms with ordinary activities and any wound or device concerns. Feeling ready is relevant, but a fixed number of days after discharge cannot account for complications or ongoing symptoms.
Assessment may consider medicines, physical symptoms, mental health and relationships. Options include treating the cause, counselling, or selected erection medicines/devices. The dated NHS page supports these categories; no product ranking or device-success claim is adopted. NHS erection guidance.
The August2026 ESC rehabilitation guideline includes sexual counselling within cardiac care and highlights symptom warnings, medication effects and referral. It also acknowledges important evidence gaps, including under-representation of women. This is an attributed professional framework; it does not independently certify the financing or efficacy of the underlying interventions. ESC2026 guideline.
Sildenafil cautions include recent heart attack or stroke, blood-pressure problems, and liver or kidney illness. Pulmonary arterial hypertension is a separate prescribing purpose. Review the exact indication, product and medicines with the prescriber. NHS sildenafil warnings.
Enhancement products, dryness care and lifestyle claims
This source set establishes no independently cleared herbal or supplement treatment for sexual dysfunction in cardiac patients. Terms such as natural, circulation support or male enhancement do not establish ingredients, medicine compatibility or clinical benefit. A product that appears to work quickly is not thereby safe for a person prescribed nitrates.
The MHRA February2026 warning describes unauthorized erection products with missing, wrong-dose, hidden or toxic ingredients. Use regulated clinical and pharmacy routes rather than social-media or messaging sellers. Local registration systems differ outside the United Kingdom; a seller badge should be checked against the appropriate official register. MHRA safety notice.
For vaginal dryness, current NHS information describes water-based lubricants and products intended as vaginal moisturizers, while advising against perfumed washes or douching. These are symptom-care categories, not a cardiac treatment. Persistent problems or unusual bleeding/discharge need assessment; do not mask them indefinitely with a retail product. NHS dryness guidance.
Meaningful outcomes and limits of clearance shortcuts
Separate sexual satisfaction, reduced distress, erection scores and cardiovascular events. Improvement in one does not establish improvement in all. A small, short trial involving mostly men may not answer questions about women, different heart conditions, pain, longer-term safety or patient acceptability.
The current ESC guideline explicitly identifies limited evidence on acceptability and cost-effectiveness of sexual screening/counselling, alongside under-representation of women. Its recommendation should be read with those qualifications. No pooled treatment-success percentage or claim that counselling prevents another cardiac event is made here. ESC2026 guideline.
A self-administered stair test, smartwatch reading or absence of symptoms on one occasion cannot substitute for medical clearance. Similarly, a normal erection does not prove normal coronary arteries, and erectile dysfunction does not establish a cardiac diagnosis. Outcomes and tests must be interpreted within their actual purpose.
Chest pain, nitrate emergencies and post-procedure symptoms
Stop the activity if chest pain, unusual breathlessness, faintness or distressing palpitations develop. Ongoing chest discomfort, spreading pain, sweating, severe breathlessness or collapse can indicate an emergency. Follow the individual cardiac emergency plan and contact emergency services when indicated; do not drive yourself for emergency treatment. NHS angina guidance.
If chest pain occurs after an erectile-dysfunction medicine, call emergency services and do not self-administer GTN. Tell responders the exact medicine and when it was taken, including an online or nonprescription product. The CUH warning is retained for this specific interaction; its fixed waiting intervals are not used as a home workaround. CUH nitrate warning.
After ICD implantation, redness, swelling, wound discharge, a blackout or a shock should be handled through the device team’s instructions. The checked CUH aftercare leaflet advises emergency help when someone feels unwell after a shock or has repeated shocks. It does not provide individualized sexual clearance; do not override the actual post-procedure plan. CUH ICD advice.
A prolonged painful erection needs urgent medical help. Suspected heart attack, severe allergic reaction or seizure requires emergency care. Tell the team about the product. NHS sildenafil warnings.
New bleeding after sex, bleeding between periods or after menopause, or unusual vaginal discharge needs clinical review. Do not assume a cardiac condition explains these symptoms. Pain is a reason to pause and seek help; intimate activity should not require enduring symptoms or pressure from another person. NHS dryness guidance.
Nitrates, PDE5 medicines and the complete product list
Nitrates include GTN used for angina and longer-acting nitrate medicines such as isosorbide mononitrate. Combining them with selected PDE5 erection medicines can lower blood pressure dangerously. The concordant warning appears in both the NHS medicine information and the CUH leaflet. Do not skip a prescribed nitrate, guess a waiting interval or borrow an erection medicine to circumvent the interaction. NHS GTN warning; CUH nitrate warning.
Sildenafil has other potential interactions, including selected blood-pressure, pulmonary-hypertension, prostate, HIV, antibiotic and antifungal medicines, and St John’s wort. The NHS also warns about poppers and other illegal drugs. Review the complete product list. NHS sildenafil warnings.
Current NHS beta-blocker information includes erection problems among possible side effects and advises review when effects persist or bother the person. That does not identify the cause in an individual or authorize stopping heart treatment. Ask whether an alternative is appropriate while preserving control of the cardiac condition. NHS beta-blocker guidance.
A product obtained privately still belongs on the cardiac medicine list. Explain the name, strength, source and use, and show the packaging when available. Different erectile-dysfunction medicines, indications and formulations cannot be treated as interchangeable.
Changing symptoms, recovery restrictions and personal precautions
People with unresolved symptoms, a recent complicated event or unclear recovery restrictions should seek specific advice before resuming more demanding activity. A restriction may concern wound healing, rhythm, symptoms or medication compatibility; ask what needs to change and how it will be reviewed, rather than assuming it lasts forever.
Someone prescribed a nitrate needs professional advice before an erection medicine. An online questionnaire may not capture an updated cardiac history.
Hormonal treatment for vaginal dryness is not suitable for everyone. Current NHS information calls for an individual discussion. Contraception, pregnancy intentions and menopause treatment should also be reviewed against the actual cardiac diagnosis and medicines; symptom relief should not be confused with proven heart protection. NHS dryness guidance.
There is no requirement to pursue sexual activity while distressed, in pain, unsure or unwilling. Clinical support should respect consent, privacy, relationship circumstances and the person’s own goals.
Preparing a private discussion and an individual follow-up plan
Prepare specific questions: When is my current condition stable enough for the activity I want? What symptoms mean I should stop or seek urgent care? Do healing restrictions still apply? Does any medicine affect function or interact with a possible treatment? What is my emergency plan if I use a PDE5 medicine?
Describe the concern in ordinary terms—pain, erection difficulty, low desire, fear, fatigue or a partner’s anxiety. Explain when it began, whether it occurs consistently, and what changed around that time. A clinician can then decide what examination, tests or referral are appropriate; no self-screening diagnosis is supplied.
NHS coronary recovery advice supports discussion with a nurse, GP or rehabilitation team and communication with a partner. Ask for a private conversation, interpreter or accessible information if needed. Discuss nonsexual closeness and mutually acceptable ways to reconnect without turning recovery into a deadline. NHS recovery guidance.
Low desire may have several causes. The current NHS page recommends seeking advice if it is worrying or a medicine/contraceptive seems implicated. Treatment should target the assessed concern; an erection tablet will not necessarily address desire, pain, relationship difficulties or fear. NHS libido guidance.
Agree how to revisit the plan if symptoms, medicines or the relationship situation change. Ask about availability, waiting times and costs for specialist or counselling services. Follow-up should measure the person’s goals and adverse effects rather than whether a generic performance standard was achieved.
Mechanisms versus human outcomes and personal clearance
Laboratory vascular, hormonal or nerve mechanisms cannot establish a personal sexual-activity clearance, medicine dose or supplement benefit. Animal findings and an attractive circulation mechanism do not replace human outcomes, interaction checks or clinical assessment. Guidance is used for attributed care and warning context, with original-study finance and comparative efficacy left unclassified where unclosed.
Funding and source roles
Who paid for the evidence?
Follow named sources to the funding and relationships disclosed in this article. Numbered article disclosures preserve notes where a source is not identified. A public or university name alone does not establish independence.
View 14 more funding disclosures
This graphic reorganizes the article's disclosures; it is not a new financial audit or independence classification. Highlighted notes show different funding relationships where available. Review funding is separate from underlying trial funding. Disclosure is not proof of falsehood, and no declared conflict is not proof of complete independence.
Medicine and device makers, enhancement-product sellers and treatment providers have commercial stakes. Actual public, provider and society income is traced separately from author and trial finance. Seller-funded or supplied-product outcomes would be Tier4/D and excluded from an independent efficacy verdict. This guide provides no brand ranking or independently cleared treatment-success claim.
The clinical subject has no single corporate owner; medicines, devices and supplements have separate commercial ownership and financial interests. Medicines, diagnostics, devices, procedures and marketed supplements create different revenue incentives. This describes financial interests rather than misconduct. Funding tier evaluates proximity to the subject; A–D credibility assesses transparency, accuracy incentives and remaining uncertainty. An unresolved link stays unresolved, and a provisional public-information label does not clear the trials behind it.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS sildenafil, July 29, 2026; selected warnings, duration anomaly excluded | National NHS DHSC-funded editorial policy and separate institutional accounts. Exact article, contributors and underlying trials unclosed. | United Kingdom; national England NHS education, Leeds institutional contact. Clinical and dispensing rules vary abroad. | Tier 1 public education route, provisional; original efficacy independence unclassified. | C provisional — actual July2026 warnings read; page contains an anomalous 36-hour duration statement, excluded with all doses/timing and rarity reassurance. Exact product and combination require review. Role: Selected current medicine cautions; duration anomaly excluded. |
| NHS erectile dysfunction, July 28, 2023; scheduled review overdue | National NHS DHSC-funded editorial policy and separate institutional accounts. Exact article, contributors and underlying trials unclosed. | United Kingdom; national England NHS education, Leeds institutional contact. Clinical and dispensing rules vary abroad. | Tier 1 public education route, provisional; original efficacy independence unclassified. | C provisional — actual 2023 body read; scheduled 2026 review overdue. Selected definition, assessment or concordant interaction warning only; licence census, timed protocols and efficacy claims excluded. Role: Dated definition, assessment and treatment categories only. |
| NHS low sex drive, May 26, 2026 | National NHS DHSC-funded editorial policy and separate institutional accounts. Exact article, contributors and underlying trials unclosed. | United Kingdom; national England NHS education, Leeds institutional contact. Clinical and dispensing rules vary abroad. | Tier 1 public education route, provisional; original efficacy independence unclassified. | B provisional — actual dated selected body read. Public-care accuracy incentive; page, authors and original-study finance unclosed. No personal clearance, dose, timetable or treatment-success estimate. Role: Current multiple-cause and concern-based assessment framework. |
| NHS vaginal dryness, July 24, 2025 | National NHS DHSC-funded editorial policy and separate institutional accounts. Exact article, contributors and underlying trials unclosed. | United Kingdom; national England NHS education, Leeds institutional contact. Clinical and dispensing rules vary abroad. | Tier 1 public education route, provisional; original efficacy independence unclassified. | B provisional — actual dated selected body read. Public-care accuracy incentive; page, authors and original-study finance unclosed. No personal clearance, dose, timetable or treatment-success estimate. Role: Selected symptom care and bleeding/discharge review. |
| NHS GTN questions, April 12, 2023; scheduled review overdue | National NHS DHSC-funded editorial policy and separate institutional accounts. Exact article, contributors and underlying trials unclosed. | United Kingdom; national England NHS education, Leeds institutional contact. Clinical and dispensing rules vary abroad. | Tier 1 public education route, provisional; original efficacy independence unclassified. | C provisional — actual 2023 body read; scheduled 2026 review overdue. Selected definition, assessment or concordant interaction warning only; licence census, timed protocols and efficacy claims excluded. Role: Dated concordant nitrate interaction; timed protocols excluded. |
| NHS coronary recovery, January 17, 2024; selected support context | National NHS DHSC-funded editorial policy and separate institutional accounts. Exact article, contributors and underlying trials unclosed. | United Kingdom; national England NHS education, Leeds institutional contact. Clinical and dispensing rules vary abroad. | Tier 1 public education route, provisional; original efficacy independence unclassified. | B provisional — actual dated selected body read. Public-care accuracy incentive; page, authors and original-study finance unclosed. No personal clearance, dose, timetable or treatment-success estimate. Role: Selected coronary recovery and professional/partner support. |
| NHS angina, March 18, 2025; selected activity/emergency context | National NHS DHSC-funded editorial policy and separate institutional accounts. Exact article, contributors and underlying trials unclosed. | United Kingdom; national England NHS education, Leeds institutional contact. Clinical and dispensing rules vary abroad. | Tier 1 public education route, provisional; original efficacy independence unclassified. | B provisional — actual dated selected body read. Public-care accuracy incentive; page, authors and original-study finance unclosed. No personal clearance, dose, timetable or treatment-success estimate. Role: Selected controlled-symptom activity and cardiac emergency warning. |
| NHS beta blockers, September 4, 2026; selected erection/side-effect context | National NHS DHSC-funded editorial policy and separate institutional accounts. Exact article, contributors and underlying trials unclosed. | United Kingdom; national England NHS education, Leeds institutional contact. Clinical and dispensing rules vary abroad. | Tier 1 public education route, provisional; original efficacy independence unclassified. | B provisional — actual dated selected body read. Public-care accuracy incentive; page, authors and original-study finance unclosed. No personal clearance, dose, timetable or treatment-success estimate. Role: Current selected erection side effect and medicine review. |
| CUH sexual advice, approved July 12, 2024 version 5; selected nitrate warning only | Separate provider 2025–26 NHS/private/research/training/donation accounts. Exact leaflet funding, named contributors and study allocations unclosed. | United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge; complete backer jurisdictions unresolved. | Tier 2 mixed provider education, provisional; original efficacy unclassified. | C provisional — actual 2024 nitrate/emergency warning read. Risk/clearance table, HF class-label inconsistency, blanket anal-intercourse claim and fixed timings excluded. Print date is not revision. Role: Selected nitrate/PDE5 emergency warning only. |
| CUH ICD aftercare, approved June 27, 2025 version 7; selected wound/shock review | Separate provider 2025–26 NHS/private/research/training/donation accounts. Exact leaflet funding, named contributors and study allocations unclosed. | United Kingdom; Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge; complete backer jurisdictions unresolved. | Tier 2 mixed provider education, provisional; original efficacy unclassified. | C provisional — actual dated selected body read. Provider accuracy/service incentives; individual authors and original-study financial chain unclosed. No universal post-implant restrictions or timetable. Role: Selected ICD wound and shock review, not sexual clearance. |
| MHRA unregulated erectile-dysfunction medicine warning, February 13, 2026 | MHRA actual regulatory/customer-fee and DHSC-grant accounts. Release includes a commercial online-provider survey link, excluded; notice/case allocations and full contributor chains unclosed. | United Kingdom; MHRA Canary Wharf, London; seized-product supply chains not fully traced. | Tier 2 public-and-fee-funded regulator safety context, provisional; seller survey not used. | B provisional — actual February2026 safety body read. Regulatory/public-safety incentives; no vendor statistics, seizure-based personal risk, or independent treatment efficacy. Role: Current unregulated-medicine safety context; seller survey excluded. |
| MHRA annual report and accounts 2025–26, actual financial/contact passages | Actual 2025–26 statutory accounts printed pp76–77 report £175.6m trading income from statutory industry regulatory fees and nonstatutory customer goods/services, plus £82.7m DHSC grant-in-aid recorded as taxpayers’ equity rather than operating income. Licence/vigilance/inspection/device fees, clinical-trial regulatory work, CPRD data-access licences and biological standards/services are described; p145 fee context read. Actual MHRA accounts. Complete named fee-payers, source-page allocation and supporting trial/author finances remain unclosed; regulator fees are not proof a particular company financed a notice. | United Kingdom; actual report printed p4 gives 10 South Colonnade, Canary Wharf, London, England. Full fee-payer jurisdictions unresolved. | Tier 3 statutory institutional self-report | B provisional — actual original read; statutory public accountability and safety-surveillance incentives, with industry fee reliance and incomplete financial chains disclosed. Institutional finance/contact only; not independent medicine efficacy evidence. Role: Actual regulatory fees and public grant routes. |
| CUH actual audited2025–26 accounts | Cambridge University Hospitals NHS Foundation Trust: actual2025–26 audited accounts documents NHS commissioner, private-patient, research/training, donation and other service income. NIHR infrastructure and industry/charity research channels disclosed; exact leaflet allocation, contributor/device-study financial chain unresolved. | United Kingdom; Cambridge University Hospitals, Addenbrooke’s/TheRosie, HillsRoad, Cambridge, England; actual original contact checked. | Tier 3 institutional financial self-report. | B provisional — actual197page audited institutional report read; statutory accountability, own reporting and no page allocation. Finance only. |
| Actual ESC cardiac rehabilitation guideline, August 2026, DOI ehag099; selected sections | Preamble states ESC development funding without healthcare-industry involvement; society income includes industry partnerships. Separate author report and trial chains not retrieved. | France; ESC association, Sophia Antipolis; multinational clinical panel. | Tier 2 professional framework, provisional; full author/trial finance unclassified. | C provisional — actual August2026 sexual-counselling section and evidence-gap table read. Separate author report and original trial finances unclosed; women under-represented. No personal clearance, event rates, exercise prescription or pooled efficacy adopted. Role: Current sexual-counselling framework and evidence limitations. |
| ESC actual current institutional income model; annual 2026 PDF unavailable | Actual institutional page lists membership, scientific events, publication/education/accreditation and life-science/medtech partnership income. Statutory-audit claim is self-reported. Annual2026 PDF exceeded access limit; totals and page allocations not verified. | France; ESC European Heart House, Sophia Antipolis. Multinational ESC/ERA collaboration; full study/supplier jurisdictions unresolved. | Tier 3 institutional financial self-report. | B provisional for actual stated income routes; institution has commercial and professional incentives, complete donor/contract and publication allocations unclosed. Financial role only. Role: Actual society income and industry routes. |
| NHS England actual audited2025–26 accounts | National NHS England: actual2025–26 audited accounts documents DHSC grant-in-aid as principal finance plus service, education/research and other consolidated income. content policy rejects advertising/corporate sponsorship. Exact page budget, contributor and underlying-trial financial chain unresolved; provider trusts have separate finances. | United Kingdom; national England patient information, institutional contact Leeds; local services and driving rules vary. | Tier 3 institutional financial self-report. | B provisional for actual statutory financial channels; no page/trial allocation or complete donor chain. |
| NHS national website funding policy | DHSC funds the national NHS website; its policy states no advertising or corporate sponsorship. Named authors, page-level budget and full underlying trial conflicts unresolved. | United Kingdom; England national public-information service. Other jurisdictions have different services. | Tier 3 editorial and financial self-disclosure. | B provisional. Explicit funding policy; actual individual declarations and implementation not audited. Financial provenance only. |
Frequently asked questions
Does having heart disease mean I cannot have sex? No universal prohibition applies. Current symptoms, treatment and recovery determine individual advice.
Does erectile dysfunction prove blocked arteries? No. Repeated symptoms warrant assessment of several possible causes.
Can I take an erection medicine with GTN? The combination can cause dangerous low blood pressure. Do not improvise around a prescribed nitrate.
What if I get chest pain after an erection medicine? Call emergency services, do not self-administer GTN, and tell responders what and when you took it.
Should I stop a beta blocker if erections change? Discuss it with the prescriber; do not independently stop cardiac treatment.
Is sexual counselling independently proven to prevent heart events? No such conclusion is established by this review. Its clinical support role and evidence limitations remain separate.
Sources and funding notes
- NHS sildenafil, July 29, 2026; selected warnings, duration anomaly excluded — Selected current medicine cautions; duration anomaly excluded.
- NHS erectile dysfunction, July 28, 2023; scheduled review overdue — Dated definition, assessment and treatment categories only.
- NHS low sex drive, May 26, 2026 — Current multiple-cause and concern-based assessment framework.
- NHS vaginal dryness, July 24, 2025 — Selected symptom care and bleeding/discharge review.
- NHS GTN questions, April 12, 2023; scheduled review overdue — Dated concordant nitrate interaction; timed protocols excluded.
- NHS coronary recovery, January 17, 2024; selected support context — Selected coronary recovery and professional/partner support.
- NHS angina, March 18, 2025; selected activity/emergency context — Selected controlled-symptom activity and cardiac emergency warning.
- NHS beta blockers, September 4, 2026; selected erection/side-effect context — Current selected erection side effect and medicine review.
- CUH sexual advice, approved July 12, 2024 version 5; selected nitrate warning only — Selected nitrate/PDE5 emergency warning only.
- CUH ICD aftercare, approved June 27, 2025 version 7; selected wound/shock review — Selected ICD wound and shock review, not sexual clearance.
- MHRA unregulated erectile-dysfunction medicine warning, February 13, 2026 — Current unregulated-medicine safety context; seller survey excluded.
- MHRA annual report and accounts 2025–26, actual financial/contact passages — Actual regulatory fees and public grant routes.
- CUH actual audited2025–26 accounts — Actual separate provider financial routes.
- Actual ESC cardiac rehabilitation guideline, August 2026, DOI ehag099; selected sections — Current sexual-counselling framework and evidence limitations.
- ESC actual current institutional income model; annual 2026 PDF unavailable — Actual society income and industry routes.
- NHS England actual audited2025–26 accounts — Separate actual national institutional finance.
- NHS national website funding policy — Financial provenance only.
The selected clinical originals and institutional financial sources were opened, with access-limited author reports and corrections identified explicitly. Actual July2026 NHS sildenafil warning body read; anomalous 36-hour statement excluded with doses, timing and rarity reassurance. Actual July2023 erectile-dysfunction and April2023 GTN question bodies read; scheduled reviews overdue, and licensing, device-success and timed self-treatment claims excluded. Actual May2026 libido, July2025 vaginal-dryness, January2024 coronary-recovery, March2025 angina and September2026 beta-blocker selected bodies read. Actual CUH July2024 sexual leaflet nitrate/emergency warning read; condition-clearance table, HF class-label inconsistency, blanket anal-intercourse/vagal claim and meal/resumption/medicine waiting intervals excluded. June2025 ICD selected wound/shock review read, not individualized sexual clearance. Actual February2026 MHRA safety release read; linked commercial online-provider survey and seizure-based personal risk excluded. Separate actual MHRA25/26 and CUH25/26 financial originals previously checked, with page and trial allocations unclosed. Actual August2026 ESC sexual-counselling section and evidence-gap table read, with development finance and society income separately checked; full separate author report and original-trial chains unclosed. No personal stair-test clearance, exercise prescription, event estimate or independent efficacy certification. Guidance, classification, emergency education and independent efficacy are distinct source roles. A full systematic review, complete society donor audit and author-by-author clearance of original treatment trials were not completed.
Last reviewed: October 4, 2026. Educational information, not a diagnosis or personal treatment plan. Use your local emergency service for an emergency.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.